intraperitoneal injection. Second, we tested whether the intraperitoneal method could detect a 37 pharmacological manipulation of glucose production. Finally, we contrasted a potential application of 38 the intraperitoneal method against the glucose-insulin clamp. We conclude that it is possible to (i) 39 quantify glucose production using an intraperitoneal injection of tracer and (ii) derive a "glucose 40 production index" by coupling estimates of basal glucose production with measurements of fasting 41 insulin concentration; this yields a proxy for clamp-derived assessments of insulin sensitivity of 42 endogenous production. 43 44 45
Introduction

46
Type 2 diabetes is typically characterized by the presence of fasting hyperglycemia, which largely results 47 from a disruption in the control of basal glucose production (9; 10). Numerous investigators have aimed 48 to quantify glucose production using isotopic tracers in order to better understand the pathophysiology 49 surrounding Type 2 diabetes and states of insulin resistance (27; 28; 38). In that regard, emphasis has 50 been placed on coupling tracer kinetics with the use of a "glucose-insulin clamp" in order to address 51 questions regarding the insulin sensitivity of endogenous glucose production (10; 16; 38). Given the 52 increase in obesity and the prevalence of insulin resistance it comes as no surprise that many methods 53 have been adapted for use in rodent models where one can readily manipulate gene expression and/or 54 examine the efficacy and mechanism of action of novel therapeutics (1-3; 21) . Unfortunately, studies are 55 typically low throughput since animals require catheterization. Herein we have considered an 56 alternative modality for quantifying glucose production in vivo. Namely, we suspected that one could 57 quantify glucose flux using an intraperitoneal bolus of a tracer which would then allow investigators to 58 envision higher throughput studies in rodent models while helping to conserve resources. The rationale 59
for considering this approach is outlined below. 60 61
Rates of glucose production can be quantified by administering an isotopically labeled tracer and then 62 measuring its dilution (28; 41). If one restricts questions surrounding glucose production to conditions of 63 a metabolic steady-state, e.g. determine rates of glucose production in a post-absorptive period, than 64 investigators must contend with two central issues when planning a study. For example, one must 65 consider (i) what type of tracer should be given and (ii) how should it be administered? 66 67
Classic studies relied on the use of radiolabeled tracers and generated interesting data regarding how 68 the type of tracer (i.e.
3
H vs 14 C) and the positional labeling could affect one's interpretation of the 69 metabolic rate(s) (18-20). For example, it was recognized that specific glucose tracers would experience 70 different dilutions and that this could be explained via glucose cycling (18-20; 41). The adaptation of 71 stable isotope tracers confirmed the early observations and allowed investigators to simultaneously mix 72 multiple isotopes in order to quantify the magnitude of the different flux rates (31). Since mass 73 spectrometry and NMR can separate the different species, it is possible to envision the routine 74 implementation of such methods (13). 75 76
As our understanding of physiology has advanced, in part due to the application of mathematical 77 models, it became clear that one could use different approaches for administering a tracer. For example, 78 one could dose a tracer via a single intravenous injection, a continuous infusion or a primed-infusion 79 (27; 28; 41). Glucose flux rates are then determined by measuring the dilution of the isotope and 80 estimating the pool size (e.g. when using the intravenous bolus approach) or by simply measuring the 81 rate of tracer dilution (e.g. when using either a constant infusion and/or a primed-infusion) (28; 38). 82
Note that this logic assumes a single (well-mixed) compartment model, which appears to be reasonably 83 valid in rodent models and in basal conditions in humans (4; 5; 14; 30). 84 85
Given the extensive history in this field, investigators have several choices regarding the design of 86 preclinical studies. However, it is unfortunate that none of the described protocols are well suited for 87 rapid (user friendly) phenotyping of rodent models. Namely, the presumption is that investigators must 88 rely on a surgical manipulation to implant catheters and/or utilize protocols which require a certain 89 degree of care in order to make delicate tail vein injections. A second study was conducted in fZDF rats following treatment with Rosiglitazone. This study relied on 111 the same diet and conditions as noted above, Rosiglitazone or 0.5% methylcellulose (vehicle) was 112 administered using an oral gavage (10 mg drug per kg body weight per day, the total dosing ran for 5 113 days over the last week of the high fat feeding period). The glucose tracer protocol and sampling 114 scheme followed the same outline as above for the intraperitoneal method. 115 116
Studies were run to quantify glucose production in mouse models using the following protocols. Male 117 C57Bl/6J mice started on a high fat diet at 6 weeks of age (D12492, Research Diets, New Brunswick, NJ; 118 60% kcal from fat, 20% kcal from protein and 20% kcal from carbohydrates, 5.2 kcal / g food), they were 119 maintained on this diet for 16 weeks. To estimate glucose production, food was removed at 8AM and 120 mice were dosed at 1PM with [U- 2 or 3 isotopomers is less than 2% at its maximum (this was determined using the same derivative but 180 running the analyses using chemical ionization in order to quantify the full isotope spectrum, 181 unpublished observations). We specifically chose this derivatization and analytical scheme since the 182 chemical workup is straightforward and robust and the analytics can be performed with a somewhat 183 basic mass spectrometer operated in a simple mode. 184 185
Insulin concentrations were determined using a standard kit (AlphaLISA Insulin, PerkinElmer). 186 187
Calculations. The fractional turnover rate of glucose was estimated by measuring the decrease in 188 glucose enrichment, data were fit using a linear regression analyses (i.e. the y-axis labeling was 189 converted to a natural log scale and the slope was determined using GraphPad Prism). The glucose pool 190 size was estimated by measuring the concentration of glucose and then assuming a volume of 191 distribution that was equivalent to 20% of body weight. In cases when [U- In cases where glucose-insulin clamps were used to study glycemic control, glucose flux was determined 198 using steady-state analyses. Namely, basal rates of appearance (Ra) of glucose are equal to rates of 199 endogenous glucose production (EGP) and determined using the standard equation:
where IE represents isotopic enrichment. During the hyperinsulinemic clamp period the tracer infusion 202 again yields the Ra however EGP is determined after subtracting the glucose infusion rate using the Table 1 contains the critical parameters that are derived from the primary concentration and 218 enrichment data (contained in Figure 1 ) and demonstrates the apparent rates of endogenous glucose 219 production. In the rat model, glucose turnover was determined using data that were collected from 45 220 to 120 minutes post-tracer administration. These time points were chosen based on the data obtained 221 in animals that had received an intraperitoneal bolus. Clearly, the delayed entry of tracer following the 222 intraperitoneal bolus requires that the sampling be shifted to a region where one can observe a steadily 223 decreasing enrichment, i.e. time points that are sampled after the tracer has moved from the 224 intraperitoneal space and into the central compartment. The data in the rat model are relatively 225 consistent regardless of the modality that is used for administering the tracer. Note that we observed 226 comparable fractional rates of turnover and equivalent estimates of pool size, therefore we calculated 227 nearly identical rates of endogenous glucose production in fZDF rats (Table 1) . 228 229
Regardless of the modality that was used to administer the tracer the mouse model also showed 230 comparable fractional rates of glucose turnover, however, there are clear differences between the 231 apparent pool size. For example, if we used the initial dilution method, i.e. pool size (mg) = tracer dose 232 (mg) / initial labeling, we would conclude that the glucose pool is 43 ± 4 mg (mean ± sem). This value 233 overestimates the pool size that is inferred by measuring the baseline concentration and assuming a 234 distribution volume that is ~ 20% of body weight (i.e. ~ 24 mg as shown in Table 1 ). The difference is ~ 235 1.8-fold (i.e. ~ 43 vs ~ 24 mg) and is consistent with the acute change in glucose concentration that is 236 seen 5 minutes after the intravenous bolus is administered, i.e. the glucose concentration increased ~ 237 1.6-fold (from ~ 195 to ~ 315 mg per dl). The stress that is associated with the intravenous tracer 238 injection and the effect this had on estimating the initial tracer dilution suggested to us that it is best to 239 estimate the pool size by assuming a distribution volume that is ~ 20% of body weight. As shown in 240 Table 1 , we observed reasonably good agreement between the apparent rates of endogenous glucose 241 production regardless of how the tracer was administered. Obviously, we obtained a slightly higher 242 value in mice receiving an intravenous bolus, which is not surprising given the transient perturbation in 243 glucose homeostasis. Note that the glucose turnover (i.e. % of the pool per min) was nearly identical 244 demonstrating that quantitation of tracer dilution was not affected by the intraperitoneal injection. 245 246 Figure 2 demonstrates the time-dependent measurements of glucose concentration and isotopic 247 enrichment in rodents following treatment with a PPAR-γ activator. Regardless of the model or the 248 specific compound, we observed a dramatic decrease in blood glucose (Panel A and C). Based on the 249 previous data that established a reasonable equivalence between the modalities for administering a 250 tracer ( Figure 1 and The effect of PPAR-γ treatment on the rate of endogenous glucose production was calculated from the 256 parameter estimates (i.e. pool size and fractional turnover rates) shown in Table 2 . Treatment of fZDF 257 rats with Rosiglitazone substantially reduced endogenous glucose production (i.e. ~ 18%, p < 0.05), 258 consistent with reports in the literature (22). As expected, Rosiglitazone led to a marked reduction in 259 fasting insulin concentration, which dramatically influenced the calculated "glucose production index" 260 (37). Similar observations were made in ob/ob mice following treatment with Pioglitazone. As expected, 261
Pioglitazone led to a dramatic decrease in blood glucose and endogenous glucose production (i.e. ~ 28%, 262 p < 0.01) (22), note that in this case glucose production approached values that were observed in 263 control (ob+) mice (p = 0.12). Consistent with data that were obtained in the rat model, treatment of 264 ob/ob mice with Pioglitazone resulted in a marked reduction in the fasting insulin concentration, which 265 led a sizeable decrease in the "glucose production index". 266 267
Another set of experiments was considered in both rodent models to cross-validate the data observed 268 to this point and to determine whether the calculated "glucose production index" would reflect clamp-269 derived estimates of insulin sensitivity of endogenous glucose production, as suggested in humans (37). Table 3 contains the glucose flux rate data 275 that are derived from the primary data contained in Figure 3 . As expected, there was a marked 276 impairment in the ability of insulin to suppress endogenous glucose production in the vehicle-treated 277 disease models however both "glitazones" improved the insulin-mediated control of glucose production 278 in the respective models. 279 280
A final set of experiments was conducted to determine the potential of this approach in normal (control) 281 rats. For example, to this point most experiments had considered studies following the modulation of 282 glucose flux in a disease model, herein we asked whether the method could detect "normal" glucose 283 flux responses. Since it is known the glucose production will decrease with extended fasting (8), we 284 measured glucose production in short-vs long-term fasted states. Figure 5 demonstrates that extended 285 fasting leads to a somewhat lower basal glucose concentration, although the tracer administration 286 tended to increase the concentration of circulating glucose this was consistent across the groups. Based 287 on the enrichment that was achieved (~ 6%), and as expected based on the load of tracer that was given 288 (0.015 mg per kg), one expects that the transient rise is glucose ( Figure 5 , Panel A) is due to some degree 289 of stress that likely results from handling of the animals and not from a substrate-mediated 290 perturbation. As summarized in shown that one can deliver tracers using osmotic pumps (43). While we have found this logic to be 311 valuable in some instances (6), the use of mini-pumps imposes an extra cost and requires that animals 312 undergo a mild sedation (to place the device) which may affect acute readouts of glucose flux. Jones and 313 colleagues have been able to derive information regarding metabolic phenotypes using a variety of 314 novel approaches that also circumvent the use of catheters (11; 12; 23). In some cases certain novel 315 approaches can unmask phenotypes that are missed by "gold-standard" methods (36). If one considers 316 the seemingly unlimited number of models and/or therapeutic probes that can be generated, it is 317 expected that the development of simplified (but reliable) methods may yield new insight into factors 318 which regulate glucose homeostasis and affect the loss of glycemic control that is seen in Type 2 319 diabetes and insulin resistant states. 320 321 We hypothesized that one could quantify glucose flux by using an intraperitoneal injection to deliver a 322 glucose tracer. This is conceptually similar to the use of an intravenous bolus for administering a tracer 323 with two obvious caveats. First, one would need to obtain some knowledge regarding when to collect 324 samples. Ideally, one should wait until the tracer has completely entered (and mixed with) the plasma 325 compartment. Second, one would have to estimate a glucose pool size by assuming a volume of 326 distribution for glucose. For example, although it is possible to determine the pool size following an 327 intravenous bolus (i.e. pool size = mass injected tracer / initial labeling) (30; 41), this logic would not 328 hold in cases where the tracer slowly enters the circulation. We previously demonstrated that one could 329 obtain comparable rates of endogenous glucose production when using an infusion method vs a bolus 330 method in rats (25 Figure 1C) we detected an 356 increase in the concentration of circulating glucose immediately following the intravenous bolus. We 357 primarily attribute this to stress which likely results from the brief restraint that is required to perform 358 the tail vein injection. In our experience, some rat models are more stable to handling and manipulation 359 therefore these transient excursions in circulating glucose concentrations are typically not seen (Figure  360 1A). 361 362
As noted above, in cases where we administered the glucose tracer via an intraperitoneal injection we 363 assumed a volume of distribution that was equal to ~ 20% of the respective body weight. This yielded a 364 glucose pool size which was virtually identical to the pool size that was determined from the initial 365 dilution of [U-
13
C]glucose following the intravenous bolus in fZDF rats (Table 1) . Glucose production 366 rates were then calculated by multiplying the respective pool sizes by the corresponding fractional 367 turnover rates ( Studies in a mouse model of insulin resistance and obesity led to similar overall conclusions regarding 373 the potential merit of using an intravenous bolus injection (Table 1) with one caveat. For example, we 374 observed comparable rates of tracer dilution (i.e. fractional turnover of the glucose pool) regardless of 375 the modality that was used to administer the tracer. The obvious caveat in the mouse model centers on 376 the sudden increase in glucose concentration following the intravenous injection ( Figure 1C ). As noted 377 earlier, if we had used the initial dilution method (i.e. pool size (mg) = tracer dose (mg) / initial labeling) 378
we would overestimate the glucose pool as compared to what we would infer by measuring the baseline 379 concentration and assuming a distribution volume that is ~ 20% of body weight (i.e. ~ 43 vs ~ 24 mg 380
shown Table 1 ). The ~ 1.8-fold difference in the apparent pool size is very consistent with the acute ~ 381
1.6-fold change in glucose concentration that is seen within 5 minutes of giving an intravenous tracer 382 bolus, this most likely reflects some degree of stress that is associated with that modality. 383 384
When we estimated the volume of distribution, by assuming that it represents ~ 20% of body weight, we 385 calculated rates of glucose production that were similar (albeit statistically different) between mice 386 which were given an intravenous vs an intraperitoneal bolus of tracer (Table 1 ). Although the current 387 data set could not definitively explain the difference between the rates of glucose production between 388 the studies, we expect that the initial perturbation of glucose concentration following the intravenous 389 injection directly altered the metabolism under investigation. In our experience, the use of an 390 intraperitoneal injection typically leads to smoother profiles of circulating glucose concentration therein 391 providing the initial motivation for us to explore this route of tracer administration as a means of 392 facilitating studies. The absolute values of glucose production that we observed in the mouse study (i.e. 393 ~ 11 mg x kg -1 x min -1 , Based on the agreement between the intravenous and intraperitoneal modes of tracer administration in 399 both rat and mouse studies, we were encouraged to examine the possibility of detecting changes in 400 glucose flux. It is well known that "glitazones" can modulate endogenous glucose production, although 401 the magnitude of those changes is not necessarily large the data are generally consistent across studies 402 (22). Therefore, rodents were either treated with Rosiglitazone or Pioglitazone for a given period and 403 glucose flux was examined following an intraperitoneal tracer administration (Figure 2) . In cases where 404 we examined the fZDF rat model, we observed reasonable reductions in glucose production following 405 treatment with Rosiglitazone (Table 2 ). The magnitude of this effect was slightly greater in the 406
Pioglitazone-treated ob/ob mouse model, which approached values of glucose production that were 407 close to control animals ( Table 2) . From these studies we concluded that the use of an intraperitoneal 408 route of tracer administration should have some merit in helping investigators quantify rates of glucose 409 production in vivo. Specifically, we could observe different flux rates between lean and obese mice and 410 we could detect an improvement in the control of glucose homeostasis following drug treatment in rat 411 and mouse models (Table 2) . Collectively, these data strongly suggest that the approach has merit. 412 413
Another set of experiments was initiated to contrast our intraperitoneal method for estimating glucose 414 production with data that would be obtained from comparable rodent models under euglycemic-415 hyperinsulinemic clamp conditions. Specifically, attention was directed towards a comparison of the 416 logic that has been described by Vangipurapu et al (37) . Briefly, although glucose-insulin clamps 417 represent a "gold-standard" for studying glucose homeostasis, it is obviously not practical to routinely 418 perform clamps especially as resources become limited. Since Vangipurapu et al have shown that it is 419 possible to derive an insulin sensitivity index of glucose production by simultaneously measuring glucose 420 production and prevailing insulin concentrations (37) we aimed to apply their logic in our preclinical 421 setting. 422 423
Our rodent models were subjected to glucose-insulin clamps in order to confirm the existence of 424 dysregulated glucose production in fZDF rats and ob/ob mice ( Figure 3 ); those studies demonstrate a 425 substantially blunted suppression of glucose production in each model (Table 3) . Since the data compare 426 very well with the calculated glucose production index for the respective models, our observations imply 427 that the "glucose production index" provides a useful surrogate of clamp-derived insulin sensitivity of 428 endogenous glucose production in rodent models (Figure 4) . Clearly, the ability to derive this production 429 index (Table 2) is facilitated by the ability to easily determine rates of glucose production, which we 430 believe can be achieved via an intravenous route of tracer administration. 431 432
A final set of experiments aimed to quantify glucose flux under more normal conditions. For example, 433 the studies that have been considered to this point were primarily aimed at studying the fundamental 434 underlying concepts surrounding the tracer kinetics and to demonstrate the application in disease 435 models following drug treatment. As noted in Figure 2 and Table 2 this approach could quantify 436 differences in glucose flux between obese mice and lean controls, as well as determine the 437 pharmacological efficacy. Consistent with those observations, we were able to detect differences in 438 glucose production in short-vs long-term fasted rats ( Figure 5 and Table 4 ). For example, it is generally 439 well known that extended fasting will result in lower glucose flux, i.e. hepatic glycogen stores become 440 depleted and glucose flux is dominated by the gluconeogenic contribution (8). Beylot and colleagues 441 clearly demonstrated the fasting will change total glucose flux (and the contribution of the respective 442 intra-hepatic flux rates) in rodents as seen in humans (24), our data ( Figure 5 and Table 4 ) are in strong 443 agreement with the expected changes in glucose production. One point that is worth mentioning 444 centers on the absolute values of EGP reported here, which are somewhat lower than those reported in 445 other studies (17). A likely explanation has to do with the body mass, our rats were approximately twice 446 the size of those used in other studies. Since data are normalized to body weight this variable could 447 contribute to the lower rate of EGP. 448 449
To summarize our findings, we have considered the use of a novel modality for administrating a glucose 450 tracer(s) which therein allows one to estimate rates of endogenous glucose production. We have 451 compared this approach, using direct experimentation, with previously accepted methods for 452 quantifying glucose kinetics in vivo. Our data demonstrate reasonable agreement between this new 453 approach and (i) the use of an intravenous route of tracer administration and (ii) the ability to detect 454 alterations in glucose production via glucose-insulin clamps. For example, we could couple these simple 455 estimates of basal glucose production and measurements of insulin levels and therein calculate a 456 glucose production index (37). Those values compare favorably with direct determinations of insulin-457 mediated control of glucose production suggesting that one may be able to circumvent the use of 458 glucose-insulin clamps in some circumstances. 459 460
In conclusion, although intraperitoneal injections are typically used in studies of glucose tolerance and 461 as a route of drug delivery, it is also possible to administer glucose tracers using this route and therein 462 estimate endogenous flux rates. Presumably the approach that is outlined here will facilitate studies of 463 glucose production however one should still consider the fact that metabolic perturbations may occur in 464 some cases when a glucose tracer is administered using an intraperitoneal injection. The two other 465 important factors to consider are centered on assumptions regarding (i) when to collect samples and (ii) 466 how to estimate the volume of distribution. As noted, this can have an obvious impact on the absolute 467 rates of glucose production. In our experience it seems that rats and mice can be sampled ~ 45 and ~ 30 468 min after the tracer is injected, respectively. This delay between the tracer injection and initial sampling 469 should ensure that enrichment is being measured after the tracer has entered the systemic circulation. 470
Obviously, investigators can modify the sampling schedule as needed. Likewise, one would need to 471 consider whether any factor(s) might influence the entry of label into the plasma. For example, the 472 presence of ascites might slow the movement of tracer. As shown herein, even in cases where we have 473 studied obese (e.g. NAFLD/NASH-like) animals we were able to apply the logic and quantify glucose flux. 474 475
It is important to note that although the discussion to this point reflects in vivo data which support our 476 logic, we have also considered questions surrounding the timing of sample collection using a more 477 general modeling and simulation strategy (see Appendix). The exercise considered a case in which in the 478 analytical error is ~ 1% of the measured enrichment (this is in the range of the general assay conditions 479 that we have used). Namely, if we expect the initial enrichment to reach 5%, an analytical error of ±1% 480 could lead to estimates of enrichment ranging from 4.95 to 5.05% (26). Since we have used [U-481 13 C 6 ]glucose and there is no detectable natural background labeling, the overall method can tolerate 482 considerable analytical error (simulations demonstrated that reasonably good fits of the tracer dilution 483 could be obtained even if the analytical error approached 10%, not shown). We remind the reader that 484 mass spectrometry error in measuring enrichments is not the only factor to consider, for example, noise 485 in the glucose pool size (i.e. measurements of glucose concentration) would also contribute to variability 486 in the apparent glucose flux; therefore, attention to animal handling is also important. Presumably one 487 can most easily probe for differences between groups if body size and/or compositional changes are 488 minimal. Nevertheless, we were able to observe differences between ob/ob and ob/+ control mice. We 489 hope that the approach developed here can be of use to investigators who are focused on 490 understanding and manipulating glucose production. is seen in other studies, i.e. there is a delay phase of entry over the initial ~ 30 min followed by a dilution 533 of the labeling to the end of the study. Data are shown as mean ± sem (n = 8 per group). 534 535 Tables.  536  Table 1 . Glucose production in rodent models. Kinetic parameters including glucose turnover and pool 537 size were estimated from the primary data ( Figure 1 ). Rates of endogenous glucose production (EGP) 538
List of
were calculated as described in Materials and Methods. Statistical analyses were performed using 2-539 tailed t-tests and assuming equal variance, no differences were observed in any measurements for fZDR 540 rats, * represents p = 0.02 for EGP in high-fat (HF) fed mice. 541 542 f Z D F r a t s (n = 6-7 per group) HF-fed C57BL/6J mice (n = 7-8 per group) IV bolus IP bolus IV bolus IP bolus Body weight (g) 289 ± 5 286 ± 4 54.2 ± 1.1 53.7 ± 0.6 Turnover (% pool per min,45→120 min)
1.83 ± 0.29 1.86 ± 0.25 2.70 ± 0.16 2.36 ± 0.10 Pool size (mg) 112 ± 11 111 ± 15 24.5 ± 1.2 24.1 ± 1.0 EGP (mg/kg/min) 6.91 ± 0.81 6.55 ± 0.58 11.9 ± 0.5 10.5 ± 0.3* 543 544 Table 2 . Glucose production in rodents following treatment with either Rosiglitazone or Pioglitazone. Kinetic parameters including glucose 545 turnover and pool size were estimated from the primary data (Figure 2) , rates of endogenous glucose production (EGP) were calculated as 546 described in Materials and Methods. The glucose production index was calculated as described (37). For studies in fZDF rats, statistical analyses 547 were performed using 2-tailed t-tests and assuming equal variance where * represents p < 0.05. For studies done in obese mice, statistical 548 analyses were done using ANOVA with Tukey's post-hoc testing across all groups where * represents p < 0.05 between Vehicle and Pioglitazone 549 of ob/+ vehicle and # p < 0.05 between Pioglitazone and ob/+ vehicle. 550 551 f Z D F r a t s (n = 6-9 per group) ob/ob mice (n = 7-8 per group) Vehicle Rosiglitazone Vehicle Pioglitazone ob/+, vehicle Body weight (g) 302 ± 3 342 ± 6* 45.9 ± 0.9 46.2 ± 0.7 26.3 ± 0.4* Turnover (% pool per min,45→120 min)
1.67 ± 0.19 3.43 ± 0.25* 1.93 ± 0.09 2.39 ± 0.19* 2.17 ± 0.05 Pool size (mg) 165 ± 24 77 ± 7* 27.6 ± 1.4 16.3 ± 0.7* 9.2 ± 0.3*# EGP (mg/kg/min) 9.33 ± 0.56 7.58 ± 0.54* 11.8 ± 0.9 8.4 ± 0.5* 7.5 ± 0.2* Insulin (ng/ml) 5.81 ± 0.45 1.04 ± 0.12* 27.9 ± 2.3 5.4 ± 1.4* 0.1 ± 0.02*# Glucose production index (EGP x [insulin])
54.6 ± 9.5 7.0 ± 0.6* 316 ± 27 46 ± 12* 0.92 ± 0.02*# 552 Table 3 . Glucose kinetics as determined using a tracer infusion protocol coupled with a euglycemic-hyperinsulinemic clamp. Glucose flux rates, 553 including the rate of appearance (Ra) and endogenous glucose production (EGP) were determined in different rodent models following 554 treatment with the respective PPAR-γ activators or methyl-cellulose vehicle. Statistical analyses were performed using 2-tailed t-tests and 555 assuming equal variance, * represents p = 0.05. 556 557 f Z D F r a t s (n = 6-8 per group) ob/ob mice (n = 6-8 per group) Vehicle Rosiglitazone Vehicle Pioglitazone Body weight (g) 322 ± 6 349 ± 8* 47.5 ± 0.4 50.1 ± 1.3 Basal Ra (mg/kg/min) 8.3 ± 0.5 7.8 ± 0.4 43.5 ± 9.3 32.8 ± 5.1 Clamp Ra (mg/kg/min) 10.9 ± 3.2 29.8 ± 2.5* 29.3 ± 4.1 43.4 ± 3.1* Clamp EGP (mg/kg/min) 5.1 ± 1.2 2.8 ± 0.6* 24.3 ± 5.1 2.4 ± 1.2* % suppression of EGP 38 ± 13 69 ± 7# 37 ± 7 95 ± 4* 558 Table 4 . Effect of nutritional status on glucose production. Kinetic parameters including glucose turnover and pool size were estimated from the 559 primary data ( Figure 5 ). Rates of endogenous glucose production (EGP) were calculated as described in Materials and Methods. Statistical 560 analyses were performed using a paired t-test, * represents p < 0.01 and ** p = 0.05. 561 562
Sprague-Dawley rats (n = 8 per study) 4 hour fast overnight fast Body weight (g) 535 ± 3 519 ± 3* Turnover (% pool per min,45→150 min)
1.74 ± 0.21 1.39 ± 0.11** Pool size (mg) 117 ± 5 95 ± 3* EGP (mg/kg/min) 3.8 ± 0.5 2.6 ± 0. 
